Masimo Co. (NASDAQ:MASI) EVP Yongsam Lee sold 5,989 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $151.83, for a total value of $909,309.87. Following the completion of the sale, the executive vice president now directly owns 78,339 shares in the company, valued at approximately $11,894,210.37. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Yongsam Lee also recently made the following trade(s):
- On Monday, July 15th, Yongsam Lee sold 12,500 shares of Masimo stock. The shares were sold at an average price of $151.82, for a total value of $1,897,750.00.
- On Thursday, June 27th, Yongsam Lee sold 258 shares of Masimo stock. The shares were sold at an average price of $145.00, for a total value of $37,410.00.
- On Monday, June 24th, Yongsam Lee sold 2,371 shares of Masimo stock. The shares were sold at an average price of $145.90, for a total value of $345,928.90.
- On Tuesday, June 18th, Yongsam Lee sold 2,728 shares of Masimo stock. The shares were sold at an average price of $145.98, for a total value of $398,233.44.
- On Thursday, June 20th, Yongsam Lee sold 9,035 shares of Masimo stock. The shares were sold at an average price of $146.60, for a total value of $1,324,531.00.
Shares of NASDAQ:MASI opened at $152.78 on Thursday. Masimo Co. has a 1-year low of $96.14 and a 1-year high of $155.13. The firm has a market cap of $8.15 billion, a price-to-earnings ratio of 50.42, a PEG ratio of 3.08 and a beta of 1.14. The stock’s 50 day moving average price is $144.26.
Masimo (NASDAQ:MASI) last posted its earnings results on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.04. The business had revenue of $231.70 million during the quarter, compared to the consensus estimate of $223.67 million. Masimo had a return on equity of 18.61% and a net margin of 22.49%. Masimo’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $0.75 EPS. Sell-side analysts anticipate that Masimo Co. will post 3.12 EPS for the current fiscal year.
MASI has been the topic of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of KLA-Tencor in a report on Tuesday, May 7th. BidaskClub raised Winmark from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. BTIG Research lowered Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price objective on the stock. in a report on Tuesday, April 16th. UBS Group reissued a “buy” rating and set a $25.00 price objective on shares of Infineon Technologies in a report on Tuesday, May 7th. Finally, Stifel Nicolaus lifted their price objective on Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, May 17th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $154.25.
Several institutional investors have recently bought and sold shares of MASI. Claybrook Capital LLC bought a new position in shares of Masimo during the 4th quarter worth approximately $25,000. West Oak Capital LLC bought a new position in shares of Masimo during the 1st quarter worth approximately $28,000. FinTrust Capital Advisors LLC bought a new position in shares of Masimo during the 1st quarter worth approximately $61,000. Valeo Financial Advisors LLC bought a new position in shares of Masimo during the 1st quarter worth approximately $69,000. Finally, NEXT Financial Group Inc lifted its position in shares of Masimo by 172.0% during the 2nd quarter. NEXT Financial Group Inc now owns 544 shares of the medical equipment provider’s stock worth $81,000 after buying an additional 344 shares during the period. Institutional investors and hedge funds own 83.02% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: Growth and Income Funds
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.